Check out your Company Bowl for anonymous work chats.
Colorado continues to emerge as a bioscience hub. Genapsys, a life science company, has announced plans to open a second location in Westminster bringing approximately 240 new jobs to Colorado. “Colorado is a fast-growing bioscience hub so we are thrilled to have Genapsys join our thriving state and help create good-paying jobs as we move Colorado forward. Our state is attracting businesses, investments and creating jobs because we are the best place in the country to live, work and thrive,” said Governor Jared Polis. “The expansion of our Colorado efforts marks an exciting milestone for Genapsys’ rapid growth,” remarked Genapsys CEO and ArcherDx founder Jason Myers. “The Denver market has emerged as a life sciences and biotech hub, offering an excellent opportunity for B2B collaboration. In addition, the local talent from universities, favorable taxes and incentives will allow us to quickly scale consumable manufacturing and increase our R&D efforts.”
The Pathologist: Combating Coronavirus Through Gene Sequencing
GenapSys - the company behind the highly-accurate, iPad-sized sequencer - just unveiled key customer validation at the JP Morgan Healthcare Conference. In 2020, they will open a pre-IPO funding round to drive R&D and scale its product worldwide.
With a size and price less than a high-end desktop computer, the highly-accurate GenapSys Sequencer is enabling any lab to own their own sequencer for the first time. It is truly a PC in a world of mainframes for genomics.
View webinar from Jackson Labs on the comparative performance data from their evaluation of the new accurate and scalable GenapSys Sequencer that has the footprint of an iPad and costs less than $10,000.
View the accurate variant calling data from the new scalable, compact, and affordable GenapSys Sequencer.
Thanks @BioCentury for the coverage of our exciting news of funding and launch of our new sequencer!
Want to know how well the new GenapSys Sequencer performs with tumor samples? Read the application note to see the performance data with various samples in cancer research.
"JAX Lab found that the mismatch error rate was lower in the GenapSys data than ... resulting in better SNP detection." Read more: http://glassdoor.com/slink.htm?key=vM21Q
